GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (NAS:MYNZ) » Definitions » EBITDA Margin %

MYNZ (Mainz Biomed NV) EBITDA Margin % : 0.00% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Mainz Biomed NV's EBITDA for the three months ended in Jun. 2024 was $0.00 Mil. Mainz Biomed NV's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. Therefore, Mainz Biomed NV's EBITDA margin for the quarter that ended in Jun. 2024 was 0.00%.


Mainz Biomed NV EBITDA Margin % Historical Data

The historical data trend for Mainz Biomed NV's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV EBITDA Margin % Chart

Mainz Biomed NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
-249.82 -52.23 -1,955.11 -4,852.45 -2,750.84

Mainz Biomed NV Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,480.00 -3,114.46 -2,987.36 -2,528.84 -

Competitive Comparison of Mainz Biomed NV's EBITDA Margin %

For the Diagnostics & Research subindustry, Mainz Biomed NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mainz Biomed NV's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mainz Biomed NV's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Mainz Biomed NV's EBITDA Margin % falls into.



Mainz Biomed NV EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Mainz Biomed NV's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-24.62/0.895
=-2,750.84 %

Mainz Biomed NV's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mainz Biomed NV  (NAS:MYNZ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Mainz Biomed NV EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Mainz Biomed NV's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mainz Biomed NV Business Description

Traded in Other Exchanges
Address
Robert Koch Strasse 5, Sirius Gutenberg Park, Mainz, RP, DEU, 55129
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.